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Volume 6Available online 23 April 2021Background: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years.
Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-
Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients
who initiated their treatment in 18 French Cancer Centres since 2008.
Patients and methods: We evaluated overall survival (OS) in the whole cohort (N ¼ 20 446) and among subtypes:
hormone receptor positive, human epidermal growth factor 2 negative (HRþ/HER2; N ¼ 13 590), HER2þ (N ¼
3919), and triple-negative breast cancer (TNBC; N ¼ 2937). We performed multivariable analyses including year of
MBC diagnosis as one of the covariates, to assess the potential OS improvement over time, and we described
exposure to newly released drugs at any time during MBC history by year of diagnosis (YOD).
Results: The median follow-up of the whole cohort was 65.5 months (95% CI 64.6-66.7). Year of metastatic diagnosis
appears as a strong independent prognostic factor for OS [Year 2016 HR 0.89 (95% CI 0.82-0.97); P ¼ 0.009, using 2008
as reference]. This effect is driven by the HER2þ subcohort, where it is dramatic [Year 2016 HR 0.52 (95% CI 0.42-0.66);
P < 0.001, using 2008 as reference]. YOD had, however, no sustained impact on OS among patients with TNBC [Year
2016 HR 0.93 (95% CI 0.77-1.11); P ¼ 0.41, using 2008 as reference] nor among those with HRþ/HER2e MBC [Year
2016 HR 1.02 (95% CI 0.91-1.13); P ¼ 0.41, using 2008 as reference]. While exposure to newly released anti-HER2
therapies appeared very high (e.g. >70% of patients received pertuzumab from 2016 onwards), use of everolimus
or eribulin was recorded in less than one-third of HRþ/HER2e and TNBC cohorts, respectively, whatever YOD.
Conclusion: OS has dramatically improved among HER2þ MBC patients, probably in association with the release of
several major HER2-directed therapies, whose penetrance was high. This trend was not observed in the other
subtypes, but the impact of CDK4/6 inhibitors cannot yet be assessed.
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- Issue 3 - 2021INTRODUCTION
Metastatic breast cancer (MBC) remains an incurable dis-
ease, and is the second leading cause of death from cancer
among women worldwide.1,2 Molecular and prognostic
classifications have divided breast cancer into three sub-
types: human epidermal growth factor receptor 2 amplifiedhttps://doi.org/10.1016/j.esmoop.2021.100114 1
ESMO Open T. Grinda et al.(HER2þ), hormone receptor positive and HER2 negative
(HRþ/HER2e, also called ‘luminal’), and HR negative,
HER2e known as ‘triple-negative breast cancer’ (TNBC).3
Over the past two decades, this division has enabled the
development of therapies adapted to each subtype.
Considering new drugs approved for HER2þMBC until 2017
inclusive, pertuzumab administered in combination with
trastuzumab and chemotherapy as first-line treatment was
demonstrated in the CLEOPATRA trial to increase overall
survival (OS) by >16 months.4 Trastuzumab emtansine,
administered in second or later lines, also demonstrated
clinically meaningful OS improvements (4 and 6.9 months,
respectively).5,6 In luminal MBC, several classes of targeted
therapies have emerged, which globally allowed doubling of
progression-free survival when combined with endocrine
therapies. These drugs include everolimus, a mechanistic
target of rapamycin (mTOR) inhibitor used in aromatase
inhibitor (AI)-resistant settings7; and three CDK4/6
inhibitors (palbociclib, ribociclib, and abemaciclib) in
both AI-sensitive and AI-resistant settings.8-13 Beyond
progression-free survival benefits, two of these CDK4/6
inhibitors have demonstrated improvements in OS.10,13
Finally, eribulin allowed a 2-months OS improvement in
HER2e MBC patients and was released in this indication in
the early 2010s14 (Supplementary Figure S1, available at
https://doi.org/10.1016/j.esmoop.2021.100114).
Beyond clinical trials, it is of utmost interest to evaluate
whether the expected benefits of these new drugs are
finally confirmed in the real-life setting.15,16 ESME (Epi-
demio-Strategy-Medico-Economical)-MBC is a very large,
nationwide, multicenter real-life database of patients with
MBC treated in the 18 French comprehensive cancer cen-
tres (FCCC).17-19 In France, the public health insurance sys-
tem covers the entire population and all fees for serious or
chronic illnesses.20 Once a drug has been approved by the
European Medicine Agency, the formal pricing and reim-
bursement decision are carried out by the ‘Haute Autorité
de Santé’ (HAS).21 Bridging mechanisms are widely available
for coverage of drugs before reimbursement. Once granted,
full reimbursement of cancer drugs is provided for all pa-
tients for whom the drugs are indicated. France can
therefore be considered adequate for real-life assessment
of treatment progresses made over time.
In this study, we analyse the effect of year of diagnosis
(YOD) on OS by breast cancer subtype, among 20 446
women who initiated treatment for MBC in the multicentre
French ESME cohort between 1 January 2008 and 31
December 2016. We also provide a description of patients'
receipt of drugs that were approved and reimbursed in
France during the inclusion and follow-up period.
PATIENTS AND METHODS
Study population
ESME-MBC (Data registration: clinicaltrials.gov identifier
NCT03275311) is a retrospective national cohort gathering
routinely collected real-world data from all consecutive
MBC women over 18 who initiated their MBC treatment in2 https://doi.org/10.1016/j.esmoop.2021.100114one of the 18 FCCCs. Data are updated annually and include
patient demographics, histopathology, outcomes, and
treatment patterns. The collected information integrates
patient data from medical records, multidisciplinary team
meeting reports, hospitalization reports, and hospitals'
pharmacy records. More details can be found in previously
published descriptions of the cohort.17-19 For this study, we
used data from MBC patients who entered the cohort be-
tween 1 January 2008 and 31 December 2016. Data were
collected until the cut-off date for data extraction (i.e. 14
April 2020). Male patients and patients whose breast cancer
subtype could not be assessed were excluded from the
analyses. Of note, the global ESME database identification
algorithm in local centres does not allow to capture all
eligible patients at the first round of selection. Patients who
entered the cohort after 2016 were therefore excluded.
Ethics approval and data protection
This analysis was approved by an independent ethics
committee (Comité De Protection Des Personnes Sud-Est II-
2015-79). No formal dedicated informed consent was
required, but all patients have been informed about the use
of their electronically recorded data and can access, rectify,
limit, or require withdrawal of their data on a dedicated
web platform at any time.22 French data protection au-
thority authorized the ESME MBC database in 2013 (regis-
tration ID 1704113 and authorization NbrDE-2013.-117). In
compliance with the applicable European regulations, a
complementary authorization was obtained on 14 October
2019 regarding the ESME research Data Warehouse.
Definitions
Breast cancer subtypes were defined according to immu-
nohistochemical (IHC) analyses carried out using metastatic
samples or, if not available, the last sample obtained from
early disease. Tumours are considered HRþ if the oestrogen
receptor (ER) and/or the progesterone receptor (PR)
expression was observed in 10% of tumour cells. HER2þ
breast cancer includes HER2 IHC 3þ scores and HER2 2þ
associated with an amplification of the HER2 gene using in
situ hybridization. A negative fluorescence or chromogenic
in situ hybridization (FISH/CISH) test, with HER2 IHC 0-2þ
score or without HER2 IHC information, leads to an HER2e
status.23-25 An HER2 IHC 2þ score without available FISH/
CISH test was considered as indeterminate HER2 status and
patients were excluded from the present analyses. The
HRþ/HER2e subtype was defined by an HRþ status (either
ER or PR positive) and an HER2e status; the HER2þ subtype
by HER2 positivity; and TNBC subtype by the absence of ER,
PR, and HER2 expression. De novo metastatic disease is
defined as the presence of metastases diagnosed within 6
months from the diagnosis of the primary tumour.
‘Relapsed’ MBC is defined as non-de novo. Metastatic dis-
ease identified on symptoms means the patient-reported
symptoms or complaints that lead to the discovery of
metastatic involvement. Systematic examination means that
metastatic disease has been identified through systematicVolume 6 - Issue 3 - 2021
T. Grinda et al. ESMO Openexaminations including clinical examination, imaging, or
blood tests, either as initial metastatic work-up (for de novo
MBC) or during follow-up. Metastasis free-interval is the
time between diagnosis of the primary breast cancer and
that of metastatic disease.Treatments
The receipt of newly released MBC treatments in the ESME
cohort was described in this report as a key objective ac-
cording to YOD of metastatic disease and subtype. Treat-
ments studied include all drugs which gained new or
extended approval from the European Medicine Agency for
metastatic/advanced breast cancer, and which were granted
reimbursement in France during the study period, including
the selection and follow-up periods. Treatments adminis-
tered in the course of a clinical trial, an expanded access
program, or for compassionate use were also included,
provided the drug complied with the prespecified criteria.
They were, however, not taken into account if the adminis-
tration of the drug within the trial was blinded. Out of all
women diagnosed with MBC in a given year, treatment
receipt is the percentage of patients who received a specific
newly released drug (or drug class) at any time during their
care, until death, or last follow-up, whatever the setting
(clinical trial, expanded access, or post approval). For HER2þ
MBC, drugs of interest, which were approved by the Euro-
pean Medicines Agency (EMA) during the period described
and were granted reimbursement, are lapatinib (16 July
2008), pertuzumab (04 March 2013), and trastuzumab
emtansine (19 March 2014). For HRþ/HER2e MBC, drugs of
interest are fulvestrant (modified 500 mg dosage; EMA
approval 15 March 2010), everolimus (23 July 2012), CDK4/6
inhibitors (palbociclib, 17 November 2016; ribociclib, 22 June
2017; abemaciclib, 26 July 2018), and eribulin (17 March
2011). For TNBC, the only drug of interest is eribulin (EMA
approval 17 March 2011; Supplementary Figure S1, available
at https://doi.org/10.1016/j.esmoop.2021.100114).Objectives
The main objective of these analyses was to analyse the
long-term impact of YOD on OS by breast cancer subtype,
and in the whole cohort. The key secondary objective was to
describe the receipt of newly released drugs over the MBC
history, by YOD.
Statistical analysis. We first described patients' characteris-
tics according to the year ofmetastatic diagnosis, in the whole
cohort, as well as in the three breast cancer subtypes (HRþ/
HER2e, HER2þ, and TNBC). The metastasis-free interval is
defined as the time between the diagnosis of primary breast
cancer and the diagnosis of metastatic disease. Quantitative
variables are described using the number of observations,
median, and first and third quartile values. Qualitative vari-
ables are described using the number of observations and
percentage distribution. The number of missing data are pre-
sented but not considered for the percentage calculation.We
carried out CochraneArmitage trend tests to assess for trendVolume 6 - Issue 3 - 2021in proportions of de novo HER2þ MBC across years of diag-
nosis, as well as the proportion of systematic examination as
identificationmethod across years of diagnosis in HER2þMBC
patients (data not shown). OS is defined as the time from the
date ofmetastatic diagnosis to the date ofdeath (any cause) or
to the date of latest news for censored patients and was
estimated using the KaplaneMeier method. The median
follow-up was estimated using the reverse KaplaneMeier
method. Multivariable Cox proportional hazard models were
carried out using a backward stepwise selection to identify
prognostic factors for OS in the whole population and in each
cancer subtype. The models were based on the candidate
prognostic factors [YOD, age at MBC diagnosis, subtypes,
metastasis-free interval (<6, 6-24, and24 months), number
of metastatic sites (<3 versus 3), and presence of visceral
metastases (yes/no)] using a conservative P value of 0.10 from
univariate analysis, except for variables highly acknowledged
as prognostic factors by literature or clinical relevance. The
independent prognostic factors included in the final models
with a significant P value of 0.05 are presented with their
hazard ratios including 95% confidence intervals. Two sensi-
tivity analyses have been carried out in the HER2 population;
one among patients with ‘relapsed’MBC, and the other in the
restricted population of patients for whom performance sta-
tus was available. These analyses reproduced the same
methodology. All analyses were carried out using R Statistical
Software (R Foundation for Statistical Computing).RESULTS
Study population features
Among 23 698 patients enrolled in the ESME database since
2008, 20 446 women were eligible for this present study
(Figure 1), of whom 13 590 (66.5%), 3919 (19.2%), and 2937
(14.3%) had HRþ/HER2e, HER2þ, and TNBC tumours,
respectively. Clinical features and patients' characteristics at
the date of metastatic diagnosis, for the whole ESME pop-
ulation, are shown in Table 1, whereas those of each sub-
type are presented in Supplementary Table S1, available at
https://doi.org/10.1016/j.esmoop.2021.100114.
Most patients and tumours characteristics, as well as the
previous receipt of adjuvant treatments, appeared stable
over time in the whole population and in subtypes. However,
two changes in the HER2þMBC cohort were significant. First,
the proportion of de novoHER2þMBC significantly increased
from 33% in 2008 to over 50% in the most recent years
(CochraneArmitage test; P < 0.001), and the rate of MBC
diagnosed by systematic examination increased from 50% to
over 60% (CochraneArmitage test; P < 0.001). At the
meantime, the proportion of de novo HRþ/HER2e and TNBC
MBC increased to a much lesser extent, from 26% and 27%,
respectively, to over 30% in the most recent years.Overall survival and prognostic analyses in the whole
study cohort
The median follow-up in the whole study population was
65.5 months (95% CI 64.6-66.7). The median OS over thehttps://doi.org/10.1016/j.esmoop.2021.100114 3
TNBC
n = 2937 (14.3%)
HR+/HER2-
n = 13 590 (66.5%)
Women with subtype-defined MBC diagnosed
between 01 January 2008 and 31 December 2017
Whole study population
(n = 20 446)
Patients who initiated treatment of a recently diagnosed
MBC in one of 18 French comprehensive cancer centers
between 01 January 2008 and 31 December 2017
(n = 23 698)
Exclusion of male patients (n = 197)
Exclusion of patients diagnosed before 2008 (n = 147)
Exclusion of patients diagnosed after 2016 (n = 1420)
Exclusion of patients whose tumor phenotype was not
established (n = 1488)
HER2+
n = 3919 (19.2%)
Sensitivity analysis (HER2+)
Relapsed (n = 2323)
Performance status available (n = 1706)
Figure 1. Flowchart.
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast cancer; TNBC, triple-negative metastatic breast cancer.
ESMO Open T. Grinda et al.full period was 38.8 months (95% CI 38.1-39.7), and the 5-
year survival rate was 33.8% (95% CI 33.1%-34.6%). Median
OS of the 2008 cohort was 36.4 months (95% CI 34.1-38.7),
whereas it was 43.9 months (95% CI 41.7-45.9) in YOD 2016
(Figure 2).
The multivariable analysis in the whole study population
identified YOD as a strong independent prognostic factor
for OS from 2013 onwards [YOD 2016, HR 0.89 (95% CI 0.82-
0.97); P ¼ 0.009], using 2008 as reference. Subtypes, age at
MBC diagnosis, number of metastatic sites, presence of
visceral metastases, and metastasis-free interval also
appeared as independent prognostic factors of OS (Table 2).Overall survival and prognostic analyses among breast
cancer subtypes
The median OS of the HRþ/HER2e subgroup was 42.9
months (95% CI 42.1-43.8), with a 5-year survival rate of
35.7% (95% CI 34.8%-36.6%). In the HER2þ subgroup,
median OS was 50.1 months (95% CI 47.6-53.1), with a 5-
year survival rate of 43.8% (95% CI 42.1%-45.6%). Lastly,
median OS of TNBC patients was 14.5 months (95% CI 13.8-
15.1) with a 5-year survival rate of 11.3% (95% CI 10.0%-
12.7%; Figure 2). Median OS appeared very stable over time
in both HRþ/HER2e patients [2008: 43.4 months (95% CI
40.9-46.5); 2016: 44.8 months (95% CI 42.5-NR)] and TNBC
patients [2008: 14.0 months (95% CI 12.3-15.9); 2016: 14.2
months (95% CI 12.1-16.5)]. However, we identified a major
improvement of median OS among patients of the HER2þ
4 https://doi.org/10.1016/j.esmoop.2021.100114cohort [2008: 39.1 months (95% CI 36.2-46.5); 2013: 58
months (95% CI 52.0-68.4); not reached from 2014
onwards].
In the multivariable analyses, YOD appeared as a strong,
sustained, independent prognostic factor for OS only in the
HER2þ subtype, and this effect increased over time from
2011 to 2016 [HR 0.83 (95% CI 0.71-0.98); P ¼ 0.032 and HR
0.52 (95% CI 0.42-0.66); P < 0.001, respectively, using year
2008 as reference]. In the three cohorts, the other inde-
pendent prognostic factors of OS were age at MBC diag-
nosis, number of metastatic sites, presence of visceral
metastases, and metastases-free interval (Table 2).
As a sensitivity analysis in the HER2þ subcohort, we
repeated the multivariable analysis in the subgroup of
‘relapsed’ HER2þ patients (N ¼ 2323). Their median OS was
41.5 months (95% CI 38.4-44.0) with a median duration of
follow-up of 69.2 months (95% CI 65.4-73.0; Supplementary
Figure S2, available at https://doi.org/10.1016/j.esmoop.
2021.100114). The same results were observed regarding
the impact of YOD on OS [e.g.Year 2016 versus 2008, HR 0.53
(95%CI 0.39-0.70); P< 0.001]. Age atMBC diagnosis, number
of metastatic sites, presence of visceral metastases, and
metastases-free interval were also independent prognostic
factors of OS in this cohort (Supplementary Table S2, avail-
able at https://doi.org/10.1016/j.esmoop.2021.100114).
As a second sensitivity analysis, we repeated the multi-
variable analysis in the HER2þ patients for which perfor-
mance status was available (N ¼ 1706). Their median OS
was 61.9 months (95% CI 58.0-66.7) with a median durationVolume 6 - Issue 3 - 2021
Table 1. Clinical features and patients' characteristics in the whole population
Year of diagnosis 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total
N 2082 2169 2237 2344 2399 2453 2389 2232 2141 20 446
Age at MBC diagnosis (years)
Median 60 59 60 60 61 61 60 61 60 60
q1q3 (50, 70) (50, 70) (50, 70) (50, 70) (51, 72) (50, 70) (50, 70) (51, 71) (50, 71) (50, 70)
Performance status, n (%)
0 260 (45%) 309 (46%) 296 (43%) 341 (45%) 390 (44%) 498 (48%) 464 (41%) 450 (41%) 489 (42%) 3497 (44%)
1 210 (36%) 233 (35%) 272 (40%) 275 (36%) 325 (37%) 339 (32%) 410 (37%) 398 (37%) 424 (36%) 2886 (36%)
2-4 111 (19%) 126 (19%) 114 (17%) 142 (19%) 170 (19%) 206 (20%) 248 (22%) 242 (22%) 262 (22%) 1621 (20%)
Missing 1501 1501 1555 1586 1514 1410 1267 1142 966 12 442
MBC diagnosis circumstances, n (%)
Symptom(s) 974 (49%) 962 (46%) 961 (45%) 1003 (45%) 1003 (45%) 1097 (45%) 1124 (47%) 1016 (46%) 785 (37%) 8925 (45%)
Systematic examination 1033 (51%) 1117 (54%) 1187 (55%) 1207 (55%) 1241 (55%) 1343 (55%) 1252 (53%) 1195 (54%) 1328 (63%) 10 903 (55%)
Missing 75 90 89 134 155 13 13 21 28 618
Metastasis-free interval, n (%)
<6 months (de novo) 570 (27%) 567 (26%) 650 (29%) 715 (30%) 733 (30%) 795 (32%) 768 (32%) 796 (36%) 805 (38%) 6399 (31%)
6-24 months 302 (15%) 302 (14%) 326 (15%) 325 (14%) 327 (14%) 330 (14%) 369 (16%) 302 (13%) 254 (12%) 2837 (14%)
>24 months 1210 (58%) 1300 (60%) 1261 (56%) 1304 (56%) 1339 (56%) 1328 (54%) 1252 (52%) 1134 (51%) 1082 (50%) 11 210 (55%)
Breast cancer subtype, n (%)
HRþ/HER2e 1378 (66%) 1405 (65%) 1473 (66%) 1591 (68%) 1609 (67%) 1636 (67%) 1602 (67%) 1487 (67%) 1409 (66%) 13 590 (67%)
HER2þ 378 (18%) 408 (19%) 407 (18%) 451 (19%) 461 (19%) 490 (20%) 451 (19%) 429 (19%) 444 (21%) 3919 (19%)
TNBC 326 (16%) 356 (16%) 357 (16%) 302 (13%) 329 (14%) 327 (13%) 336 (14%) 316 (14%) 288 (13%) 2937 (14%)
Visceral metastases, n (%)
Yes 1171 (56%) 1245 (57%) 1305 (58%) 1381 (59%) 1370 (57%) 1412 (58%) 1362 (57%) 1303 (58%) 1182 (55%) 11 731 (57%)
No 911 (44%) 924 (43%) 932 (42%) 963 (41%) 1029 (43%) 1041 (42%) 1027 (43%) 929 (42%) 959 (45%) 8715 (43%)
Number of metastatic sites at MBC diagnosis, n (%)
<3 1711 (82%) 1766 (81%) 1787 (80%) 1875 (80%) 1885 (79%) 1927 (79%) 1878 (79%) 1715 (77%) 1639 (77%) 16 183 (79%)
3 371 (18%) 403 (19%) 450 (20%) 469 (20%) 514 (21%) 526 (21%) 511 (21%) 517 (23%) 502 (23%) 4263 (21%)
Chemotherapy in neoadjuvant setting (in relapsed patients), n (%)
Yes 1050 (69%) 1147 (72%) 1114 (70%) 1187 (73%) 1184 (71%) 1201 (72%) 1190 (73%) 1062 (74%) 980 (73%) 10 115 (72%)
No 462 (31%) 455 (28%) 473 (30%) 442 (27%) 482 (29%) 457 (28%) 431 (27%) 374 (26%) 356 (27%) 3932 (28%)
Metastasis-free interval is the period between the date of primary breast cancer diagnosis and the date of the metastatic diagnosis.






















Figure 2. Overall survival in the whole ESME population and in breast cancer subtypes according to the YOD.
(A) Overall survival in the whole ESME population by year of metastatic diagnosis. (B) Overall survival in the HRþ/HER2eMBC subcohort by year of metastatic diagnosis.
(C) Overall survival in the HER2þ MBC subcohort by year of metastatic diagnosis. (D) Overall survival in the TNBC MBC subcohort by year of metastatic diagnosis. CI,
confidence interval; ESME, Epidemio-Strategy-Medico-Economical; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast
cancer; mths, months; NR, not reached; OS, overall survival (median); TNBC, triple-negative metastatic breast cancer; YOD, year of metastatic diagnosis.
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Table 2. Multivariable analysis of OS within the whole ESME population and among subtypes
Characteristic Whole cohort HRD/HER2e HER2D TNBC
Hazard
ratio
95% CI P value Hazard
ratio
95% CI P value Hazard
ratio
95% CI P value Hazard
ratio
95% CI P value
Year of MBC diagnosis
2008 1 1 1 1
2009 0.99 0.92-1.06 0.67 1.04 0.95-1.13 0.41 0.91 0.77-1.07 0.24 0.94 0.80-1.10 0.42
2010 1.00 0.93-1.07 0.91 1.02 0.94-1.11 0.61 0.92 0.78-1.08 0.31 0.97 0.82-1.13 0.67
2011 0.97 0.90-1.03 0.31 1.01 0.93-1.10 0.80 0.83 0.71-0.98 0.032 0.90 0.76-1.06 0.21
2012 0.95 0.89-1.02 0.14 0.94 0.86-1.03 0.17 0.84 0.71-0.99 0.039 1.08 0.92-1.27 0.36
2013 0.90 0.84-0.96 0.003 0.97 0.88-1.05 0.44 0.72 0.60-0.85 <0.001 0.87 0.74-1.03 0.10
2014 0.91 0.84-0.98 0.009 1.04 0.95-1.14 0.42 0.63 0.52-0.76 <0.001 0.78 0.66-0.93 0.005
2015 0.90 0.84-0.98 0.011 1.03 0.94-1.14 0.52 0.62 0.50-0.76 <0.001 0.83 0.70-0.99 0.038
2016 0.89 0.82-0.97 0.009 1.02 0.91-1.13 0.77 0.52 0.42-0.66 <0.001 0.93 0.77-1.11 0.41
Age at MBC diagnosis (10-year increase)
1.12 1.11-1.14 <0.001 1.14 1.12-1.16 <0.001 1.18 1.14-1.22 <0.001 1.04 1.01-1.07 0.008
No. of metastatic sites at MBC diagnosis
<3 1 1 1 1
3 1.54 1.47-1.60 <0.001 1.40 1.32-1.48 <0.001 1.75 1.57-1.94 <0.001 1.84 1.67-2.04 <0.001
Presence of visceral metastases
No 1 1 1 1
Yes 1.46 1.40-1.52 <0.001 1.48 1.41-1.55 <0.001 1.56 1.41-1.73 <0.001 1.43 1.30-1.57 <0.001
Metastasis-free interval
<6 months (de novo) 1 1 1 1
6-24 months 2.29 2.17-2.42 <0.001 2.37 2.19-2.57 <0.001 2.70 2.38-3.06 <0.001 1.67 1.51-1.85 <0.001
>24 months 1.15 1.10-1.20 <0.001 1.15 1.09-1.21 <0.001 1.37 1.24-1.51 <0.001 0.87 0.78-0.97 0.009
Cancer subtype
HRþ/HER2e 1
HER2þ 0.79 0.75-0.83 <0.001
TNBC 2.28 2.17-2.39 <0.001
Bold value indicates the significant P value < 0.05.
CI, confidence interval; ESME, Epidemio-Strategy-Medico-Economical; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast cancer;
OS, overall survival; TNBC, triple-negative metastatic breast cancer.
ESMO Open T. Grinda et al.follow-up of 61.3 months (95% CI 58.2-64.3). The same
trends were observed regarding the impact of YOD on OS,
although they lost significance in most YOD cohorts (e.g.
Year 2016 versus 2008, HR 0.75; 95% CI 0.54-1.05; P ¼
0.093). Age at MBC diagnosis, number of metastatic sites,
presence of visceral metastases, and metastases-free in-
terval again were independent prognostic factors of OS in
this cohort (Supplementary Table S3, available at https://
doi.org/10.1016/j.esmoop.2021.100114).Metastatic treatments over the MBC history, by year of
diagnosis and subtypes
Figure 3 and Supplementary Table S4, available at https://
doi.org/10.1016/j.esmoop.2021.100114, describe the rate
of patients in a given YOD who received at least once during
the management of their MBC a drug that was released and
reimbursed in France during the study period. Among pa-
tients in the HER2þ cohort, receipt of pertuzumab
increased very rapidly, up to >70% of patients from 2016
onwards. Receipt of trastuzumab emtansine was confirmed
in up to 42% of the patients (cohort 2014). By contrast,
among patients with HRþ/HER2e MBC, exposure to ever-
olimus and eribulin has never exceeded 26% (higher score
observed in YOD 2012 and 2013). Fulvestrant has been used
in up to 43% of the patients (YOD 2012). By contrast,
exposure to CDK4/6 inhibitors seems to increase rapidly,
with already 31% of patients (YOD 2016) being exposed.8 https://doi.org/10.1016/j.esmoop.2021.100114Finally, among patients with TNBC, eribulin use never
exceeded 32% (YOD 2014).DISCUSSION
MBC represents a major social, medical, and economic
burden worldwide, with over 620 000 deaths in 2018.26
Several MBC innovative treatments have been released on
the market over the past 12 years, with ranking according to
the ESMO Magnitude of Clinical Benefit Scale (MCBS)
ranging from 2 to 5.27 Regarding the high medical need, and
also the costs of these medications, it is of utmost impor-
tance to carefully scrutinize whether the expected impacts
of these drugs are observed in real-life. The ESME-MBC
cohort is one of the largest real-world databases of MBC,
in a country with universal drug access. It therefore pro-
vides an appropriate material for such evaluation.
Our study provides two major results: one is the
description of the evolution of OS over time, together with
evaluation of the independent effect of YOD on outcome in
the whole population and among each MBC subtype; the
other is the description of the uptake of newly released
drugs in the same cohorts of patients classified by YOD.
Among nearly 20 500 women with MBC diagnosed be-
tween 2008 and 2016 and followed until April 2020, we
observed a modest OS improvement, which appeared to be
almost fully driven by the HER2þ subgroup. In this sub-


























































































































































Figure 3. Receipt of newly released treatments per subtype and year of diagnosis.
*Proportion of all patients diagnosed with an MBC subtype in a given year who received a specific newly released drug at any time during their care, until death, or end
of follow-up, whatever the setting (drugs could be used within clinical trials, expanded access programs, or post approval). Any CDK4/6 inhib, palbociclib, ribociclib,
abemaciclib; MBC, metastatic breast cancer; T-DM1, trastuzumab-emtansine.
T. Grinda et al. ESMO Open2008; 58 months (95% CI 52.0-68.4) in 2013; and was not
reached from 2014 onwards. Multivariable analyses,
including year of metastatic diagnosis as a covariate,
confirm the independent impact of YOD on OS in the
HER2þ cohort with a smaller effect in the whole popula-
tion, a marginal one among TNBC patients, and none among
women with HRþ/HER2e cancers.
Of note, the structure of the HER2þ MBC population has
notably changed over time. The proportion of de novo
HER2þ MBC significantly increased from 33% in 2008 to
over 50% more recently, and the proportion of MBC diag-
nosed by systematic examination significantly increased from
50 to over 60%. Of note, the proportion of de novo MBC
patients also increased in the other cohorts, but with less
magnitude. This observation among HER2þ MBC patients is
consistent with recent studies and registries.6,7,21 It reflects,
on the one hand, improved care at the localized stage and
thus the number of patients cured at this stage;28-31 and on
the other hand, the improved sensitivity of the diagnostic
tests allowing better staging.32 This contributes to increased
OS by a Will Rogers phenomenon,33 as de novo MBC
patients have a better prognosis than the relapsed ones,
who may suffer an adjuvant therapy-related shortening of
survival effect (ATRESS).34,35 However, the present data
clearly showed that OS-relative improvement across YOD
was maintained among patients with relapsed HER2þ MBC
and equivalent to that of the whole HER2þ cohort.
It may be quite surprising that, despite improved early
treatments, the number of new HER2þ MBC cases in ESME
remains stable over time. As mentioned, changes in in-
dications and use of metastatic work-up at diagnosis (and
possibly during follow-up) could explain these figures. This
could lead to an artificial survival advantage through earlierVolume 6 - Issue 3 - 2021diagnosis of the metastatic stage.36,37 However, the
observed effect of YOD on OS is independent of these two
covariates and cannot be questioned.
In parallel to OS results by YOD, our study shows that the
uptake of newly released drugs has been very heterogenous
according to tumour subtypes. On one side, the receipt of
pertuzumab appears very high: >70% of HER2þ patients
received it from 2016 onwards, which is close to what
would be expected given the presence of patients with
early relapses under trastuzumab, changes in HER2 status,
or contraindication to HER2-targeted therapies. Besides, the
receipt of trastuzumab emtansine is quite high and overall
in line with expectations in a real-life setting. Indeed, in this
setting, long remissions, as in the case of double anti-HER2
blockade, artificially reduce the rate of treatment uptake
because patients have not yet been treated during the in-
clusion period. This is in line with recent real-world data
generated from pharmaceutical electronic records in a large
cohort of HER2þ BC patients.38 By contrast, the receipt of
eribulin, released in 2011 for HER2e MBC, has never
exceeded 32% and 26% of TNBC and HRþ/HER2e patients,
respectively. Besides, among patients with HRþ/HER2e
MBC, exposure to everolimus peaked at only 25.5% in pa-
tients with YOD 2013. The low fulvestrant use (up to 43% of
the patients with YOD 2012) was also unexpected. This
major underuse of fulvestrant and everolimus may be
explained by the very high rate of chemotherapy use as
first-line (and subsequent lines) treatment for HRþ/HER2e
MBC among French clinicians, until recently.19 In addition,
there may be an underestimation bias in ESME for second
lines or over, as treatments potentially administered outside
the inclusion centre could be under-reported, but this
represents a minority of patients lost to follow-up after thehttps://doi.org/10.1016/j.esmoop.2021.100114 9
ESMO Open T. Grinda et al.first line. Moreover, uptake rates as estimated in this study
are crude rates, among a given cohort of patients taken at
MBC diagnosis; they do not exclude those who would not
be candidate for a given drug, as they died meanwhile, for
instance. However, exposure to CDK4/6 inhibitors seems, in
contrast, to increase rapidly, with 31% of patients (YOD
2016) already receiving these drugs. Of note, our analysis is
purely descriptive in ongoing cohorts, and does not intend
to assess the exact rates of treatment prescriptions in
specific, approved situations, which is almost not feasible in
such an observational cohort. Furthermore, treatments'
receipt includes postreimbursement access, as well as pre-
scription as part of clinical trials, expanded access programs,
or others.
The median OS of HER2þ ESME MBC patients in YOD
2013 (date of authorization of pertuzumab in France)39 was
58.0 months (95% CI 52.0-68.4), which strikingly re-
capitulates in a real-world setting the impressive 56.5
months' median OS reported in the final analysis of the
CLEOPATRA trial.40 Although we cannot provide a direct
causality demonstration, our results confirm that the
release of high-impact drugs such as pertuzumab and
trastuzumab emtansine (ESMO MCBS impact 5 and 4,
respectively), together with a high drug receipt/penetrance,
allows for major real-life benefits.
Finally, we have to acknowledge that the low rate of use
of drugs with an expected lower clinical impact, such as
everolimus and eribulin (ESMO MCBS impact 2 and 2,
respectively), does not seem to be associated with an
improvement in OS in a public health-level population.41
The observed underuse of eribulin may be partially linked
to restricted reimbursement in late treatment lines, which
was not, however, the case for everolimus. This raises major
questions on how new drugs should be managed at a public
health level, and whether releasing costly drugs that are not
used properly is relevant. Of note, our data are too early to
allow the evaluation of the impact of CDK4/6 inhibitors in
real life. This evaluation shall be possible in 2-3 years from
now.
The strengths of our study include a very large number of
patients, long follow-up, high-quality data with clinical trial-
like methodology to gather data from patients' files and
other resources, homogenous multicentric setting in
comprehensive cancer centres, large and homogenous ac-
cess to care, and innovations in the population. All of these
factors contribute to establishing confidence in our results
in terms of real-world evidence, defined as clinical evidence
derived from the analysis of real-world data.
The main limitations of our study are inherent to its
retrospective and observational design. It is very difficult to
retrospectively define treatment indications, and treatment
choices are made by physicians. Drug exposure could
therefore only be assessed ‘macroscopically’. Data on
quality of life and safety are not available. Patients are
recruited by FCCCs, which may not fully represent the
French or European general population. In particular, the
median age of our cohort is a bit lower than expected due
to a slight under-representation of older women (26% of10 https://doi.org/10.1016/j.esmoop.2021.100114women in ESME are aged 70 years) who are less
frequently referred to comprehensive cancer centres. This
could lead potentially to a slight overestimation of OS.42
Performance status, an important predictor of OS, was
available in only 40% of the files, and could not be included
in the main analyses. Sensitivity analyses conducted among
patients with PS data available, however, gave the same
results as the main analyses. This real-life public-health-level
approach cannot provide a formal demonstration of the
causal impact (or absence of impact) of treatments on OS,
but only provides time relations and observations, which we
nevertheless consider relevant.
In conclusion, in this large-scale, real-life setting and
among almost 20 500 patients with MBC, we observed a
dramatic improvement of OS among HER2þ MBC patients
since 2013, most likely in relation to the release of two
several major HER2-directed therapies, whose penetrance
was high. This was not observed in HRþ/HER2e and TNBC
subtypes, where OS has not improved over time, and
penetrance of new drugs released during the period (eri-
bulin and everolimus) was low. Our data do not yet allow to
evaluate the impact of CDK4/6 inhibitors. These results
overall question the necessary public health strategy asso-
ciated with the release of new drugs if a real-life impact is
expected, and the role of real-life data on the final assess-
ment of treatment innovations.
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